Objectives: The aim of this study was to review outcomes in patients with PLE following the Fontan operation
(Ann Thorac Surg 2010;89:837-42) 2010 by The Society of Thoracic Surgeons our patients with single-ventricle palliation, as survivors of the Fontan operation continue to age
1 , 2 ]
Oral budesonide is an effective therapy for treating protein-losing enteropathy after the Fontan operation
2 Mortality after PLE is high, five-year survival at only 46% to 59%
Protein losing enteropathy is a serious condition usually caused by an underlying gastrointestinal problem or previous heart surgery
127 Some practitioners use parenteral dexamethasone Although protein-losing enteropathy (PLE) implies an intestinal disease associated with the small bowel, the term "protein-losing enteropathy" is commonly used to also include loss of protein from the colon, stomach, and, rarely, the esophagus
Budesonide for protein losing enteropathy in patients with fontan circulation: a systematic review and Protein-losing enteropathy (PLE) is not a single disease but a symptom
Medical treatment, predominantly pulmonary vasodilator and/or systemic anti-inflammatory therapy with budesonide, was initiated in 28 patients
Charts were Protein-losing enteropathy is associated with Fontan palliation for single-ventricle physiology and has been difficult to treat
The patient underwent a successful cardiac transplantation and budesonide was stopped
3,4 Protein losing enteropathy is characterized by the loss of serum proteins into the gastroin- Protein-losing enteropathy occurs in 5% to 15% of patients after the modified Fontan operation and is an extremely difficult complication to treat successfully [2, 7]
The diet must be especially digestible and high in protein (20-25% protein on a dry matter basis) so as to replace all the protein being lost through the leaky GI tract
In many cases, this loss of protein is due to abnormalities in lymphatic flow
Protein-losing enteropathy (PLE) is not a specific disease, but is described as a group of diseases that cause the loss of proteins from the bloodstream into the gastrointestinal (GI) tract
09
cannot be compensated by the liver
1%
Strictly, any condition leading to abnormal protein loss Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) is characterized by abdominal pain and diarrhea, primary intestinal lymphangiectasia, hypoproteinemic edema, and malabsorption
A poor outcome has been reported for dogs with protein-losing enteropathy, with a median survival time of less than 6 months, except for Yorkshire Terriers (median survival time of 44 months)
Background: Protein-losing enteropathy (PLE) because of chronic inflammatory enteropathy (CIE) in dogs is often treated with a combination of glucocorticoids and second-line immunosuppressant (SLI)
While a subset of patients with Fontan failure require a heart transplant (HT) for systemic pump dysfunction, a number of patients require HT for refractory PLE in the setting of normal cardiac function
6 Manipulation of the capsules targets the gastric and proximal small intestinal mucosa with a topical steroid thus avoiding Oral Budesonide Treatment for Protein-Losing Enteropathy in Fontan-Palliated Patients A poor outcome has been reported for dogs with protein-losing enteropathy, with a median survival time of less than 6 months, except for Yorkshire Terriers (median survival time of 44 months)
Randomized, controlled trial of budesonide and prednisone for the treatment of idiopathic inflammatory bowel disease in dogs
protein-losing enteropathy, primary biliary cirrhosis, and lymphocytic colitis
Response to oral budesonide, side effects, and serum albumin levels before the treatment and at first, fourth, and ninth months of the budesonide Corticosteroids including budesonide, have been used in patients with protein-losing enteropathy associated with collagen vascular diseases, inflammatory bowel disease, or after Fontan procedure to complex congenital heart disease
Oral budesonide is an effective therapy for treating protein-losing enteropathy after the Fontan operation
PLE is characterized by the enteric loss of proteins, such as albumin, immunoglobulins, and clotting factors
Oral Budesonide Treatment for Protein-Losing Enteropathy in Fontan-Palliated Patients Materials and Methods
Treatment strategies for protein-losing enteropathy in Fontan-palliated patients - Volume 30 Issue 5
When the serum albumin level increased, the budesonide
Recent studies have shown that oral budesonide can be used to improve albumin level in patients with protein-losing enteropathy (PLE) following Fontan procedure
In 15 patients, a stable remission could be achieved by medical or surgical procedures (n = 3 Intestinal inflammation is a component of the pathophysiology of protein-losing enteropathy after the Fontan operation
Cases were excluded for lack of budesonide
Recent studies have shown that oral budesonide can be used to improve albumin level in patients with protein-losing enteropathy (PLE) following Fontan procedure
Protein-losing enteropathy due to restrictive cardiomyopathy was diagnosed and oral budesonide was started
3,4 Protein losing enteropathy is characterized by the loss of serum proteins into the gastrointestinal (GI) tract lumen
3,4 Protein losing enteropathy is characterized by the loss of serum proteins into the gastroin- Protein-losing enteropathy (PLE) is an enigmatic ailment that strikes children and young adults after a Fontan operation
When fluid cannot be held within the vasculature, it leaks out into body cavities (effusion) or into tissue in general as edema (swelling)
However, there has never been a systematic review and meta-analysis to confirm this finding
In many cases, this loss of protein is due to abnormalities in lymphatic flow
J Vet Intern Med 2000;14(1):68-80
Medical treatment of dogs with SRE/IRE usually involves the administration of glucocorticoids (predniso[lo]ne or budesonide) and/or other immunosuppressive drugs Disease severity and chronicity dictate the diagnostic and therapeutic approach to dogs suspected of having protein-losing enteropathy (PLE)
Protein-losing enteropathy (PLE) is a complex disorder characterized by enteric protein loss and often is associated with cardiovascular abnormalities, particularly those with elevated central venous pressure
Protein-losing enteropathy is an uncompensated loss of plasma proteins in the intestine, indicated by elevated alpha 1 -antitrypsin levels in Budesonide was administered to 9 patients (4 male) with protein-losing enteropathy after the Fontan operation
DOI: 10
063 Corpus ID: 34842090; Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation
associated with the abnormal loss